Answers are grounded in this paper and cite their sources.
This Monte Carlo study evaluates and compares the radiosensitization potential of gold (Au) and platinum (Pt) nanoparticles (NPs) in prostate low-dose-rate (LDR) brachytherapy using 125 I and 103 Pd sources. Using the TOPAS Monte Carlo software, Au and Pt NPs (30 and 100 nm) were uniformly distributed within a tumor volume at concentrations of 7, 18, and 30 mg/g within a modified MIRD male phantom. Dose enhancement factors (DEFs) and dose volume histograms (DVHs) were calculated for both source types. Au NPs consistently outperformed Pt NPs, with maximum DEFs of 2.58 for Au versus 2.53 for Pt ( 125 I, 30 mg/g, 100 nm). DEF increased with concentration and NP size, with 125 I yielding greater enhancement than ¹⁰³Pd due to its lower photon energy. DVH analysis demonstrated selective tumor dose escalation (tumor Dmean increased from 239.8 Gy to 282.2 Gy for Pt with 103 Pd) with negligible impact on organs at risk. Photoelectric energy deposition increased by up to 20.7-fold with NP addition, correlating with observed DEF trends. In conclusions both Au and Pt NPs significantly enhance tumor dose in LDR brachytherapy while sparing adjacent organs, supporting an improved therapeutic ratio. The near-equivalence of Au and Pt NP performance suggests Pt may represent a viable, cost-effective alternative for clinical translation. These findings provide a dosimetric foundation for future experimental and clinical investigations.
No takes yet. Share an insight, caveat, or question.
Atefi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: